ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE

August 27, 2019

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

Labor Day Tribute from Actoverco

May 1, 2025

Author:

Acteropharma

International Labor Day is a global tribute to the unwavering will and tireless hands that shape the future. It is a meaningful occasion to honor those whose dedication, expertise, and commitment drive the engines of progress and prosperity.

Actero, Sponsor of the 9th International Radio-Oncology Congress

March 11, 2025

Author:

Acteropharma

From January 30 to February 1, the 9th International Radio-Oncology Congress was held with the aim of advancing scientific programs in the community and supporting the expansion of cancer research.

Welcoming Nowruz with “Kindness and Generosity”

March 5, 2025

Author:

Acteropharma

For several years, in a commendable initiative aligned with this national tradition, March 4 has been designated as the National Day of Kindness and Generosity in our country’s official calendar.